REG - Indivior PLC - Indivior Dec. 7 Capital Markets Day Highlights

IndiviorAnnouncement

07/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221207:nRSG8290Ia&default-theme=true

RNS Number : 8290I  Indivior PLC  07 December 2022

 

Indivior Capital Markets Day Highlights Strategy for Shareholder Value
Creation

and Attractive Medium-Term Profitable Growth Outlook

 

- Peak Annual Net Revenue Potential for SUBLOCADE® Increased to >$1.5
Billion

- Attractive and Scalable Business Outlined - Expects Strong Net Revenue
Growth and Operating Margin Expansion Over the Medium-term

- Disciplined Approach to Capital Allocation Maintained

- NASDAQ Listing Targeted for Spring 2023

 

This Release Contains Inside Information.

Slough, UK, and Richmond, VA, December 7, 2022 - Indivior PLC (LON: INDV) will
hold a Capital Markets Day today in New York City. The event will be hosted by
Mark Crossley, Chief Executive Officer, along with members of the Indivior
executive leadership team and will detail the Company's strategic growth plans
and roadmap for delivering long-term shareholder value.

 

"We have made tremendous progress executing on our strategic priorities," said
Mark Crossley. "We are the pioneer and global leader in addiction treatment
and science and are well-positioned to transform the lives of the increasing
number of patients affected by the opioid crisis, one of the most urgent
public health emergencies of our time. Today, my team and I are excited to
provide a deep review of our business and to highlight the compelling
opportunities we have to innovate in the treatment of addiction and serious
mental illness while delivering profitable growth and significant value
creation for shareholders."

 

·    Increases SUBLOCADE peak annual net revenue (NR) expectations to
>$1.5 billion

 

Indivior expects SUBLOCADE® (buprenorphine extended-release) injection to
achieve a NR run rate of $1 billion by the end of 2025, driven by its focus on
further developing the Organized Health Systems (OHS) channel and pursuing the
large opportunity in the U.S. Justice System. Longer term, based on the
expected positive market dynamics for buprenorphine medication-assisted
treatment (BMAT) and on continued execution against its OHS strategy, Indivior
now expects to deliver SUBLOCADE peak potential NR of >$1.5 billion.

 

·    Expects to achieve attractive double-digit % NR compounded annual
growth rate (CAGR) over the medium-term

 

Indivior expects to achieve a double-digit percentage NR CAGR over the
medium-term, driven primarily by SUBLOCADE in the United States and growing NR
contribution from PERSERIS® (risperidone for extended-release injection).
 Within this outlook, which is based on its current business portfolio,
Indivior also expects a return to NR growth in the Rest of the World driven by
new products SUBLOCADE (SUBUTEX® PR) and SUBOXONE® (buprenorphine/naloxone)
Film. Additionally, the Company assumes the U.S. market share of SUBOXONE
Film, which it does not promote, will trend towards historical analogs for
genericized medicines.

 

·    Operating margin expansion opportunity from scalable business model

 

Indivior expects to achieve significant operating margin expansion over the
medium-term driven by an improving gross margin and focused management of
operating expenses. Following the significant structural growth investments
behind SUBLOCADE and PERSERIS in the past two years, selling, general and
administrative  (SG&A) expenses are expected to grow at a more moderate
pace and to decline as a percentage of NR. This impact is expected to be
partly offset by an increase in R&D expenses as a percentage of NR towards
industry benchmarks as the Company seeks to build a strong and balanced
pipeline focused on addiction treatments.

 

·    Disciplined capital allocation approach focused on driving growth and
potential returns of excess cash

 

In the past two years, Indivior's healthy balance sheet and improved cash flow
have supported a balanced approach towards capital allocation, focused on
investment in key growth priorities, diversifying the business, delivering
shareholder returns and meeting other stakeholder obligations. The recently
announced definitive agreement to acquire Opiant Pharmaceuticals, Inc.
(NASDAQ: OPNT) is indicative of Indivior's commitment to diversify its product
portfolio and to expand its global leadership in addiction treatment and
science.

 

·    Listing on NASDAQ targeted for the Spring of 2023

 

At its Extraordinary General Meeting (EGM) in September of this year, Indivior
received strong support from its shareholders for an additional share listing
in the United States. Having carefully evaluated the available options,
Indivior has chosen NASDAQ as its U.S. trading venue. The additional listing
is expected to elevate Indivior's profile in the Company's largest market and
to attract a broader group of biopharma-focused investors and analysts.
 

 

The Group reiterates its FY 2022 guidance published on October 27, 2022.

 

Event Details

Today's event will begin at 8:30am EST and conclude at 12:30pm EST. Due to
limited availability, in-person participation is limited to institutional
investors and analysts. For those wishing to attend in person, please RSVP to
investorrelations@indivior.com (mailto:investorrelations@indivior.com) and
further location details will be provided.

 

Further details can be found at cmd.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.indivior.com%2Fen%2Finvestors%2Fcapital-markets-day&data=05%7C01%7Ctimothy.owens%40Indivior.com%7Caaa09a2376964a82cf3808dab8e1606d%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638025575432590096%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=XG8xEVGLdU08fstzaobMJ3HnUEoT%2Blc2%2FVkC%2FumuKO4%3D&reserved=0)

To access the live webcast, please click INDV CMD 2022
(https://wsw.com/webcast/cc/indv.l/1540962) .

 

A webcast replay will be available after the event has concluded.

 

The person responsible for making this announcement is Kathryn Hudson, Company
Secretary.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs approximately 1,000
individuals globally and its portfolio of products is available in 39
countries worldwide. Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.indivior.com%2F&data=04%7C01%7Cjason.thompson%40Indivior.com%7C50524c1bfa284722f7ee08da13118474%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843263192018647%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=XV57BWLOjOnGhAQJWI0WKEK4%2FXf0M9QcOEiYwwerqho%3D&reserved=0)
to learn more. Connect with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Findivior&data=04%7C01%7Cjason.thompson%40Indivior.com%7C50524c1bfa284722f7ee08da13118474%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637843263192018647%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=ztGNJPoRRJvCmxgR2tqSP1oJuDdNpAGH7hPFUtuOHcA%3D&reserved=0)
.

 

 

 

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com
(mailto:jason.thompson@indivior.com)

 

 

Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or timothy.owens@indivior.com
(mailto:timothy.owens@indivior.com)

 

Forward-looking Statement:

Important Cautionary Statement

This presentation contains certain statements that are forward-looking.
Forward-looking statements include, among other things, statements regarding
future growth and growth rates, future profitability, operating results, and
cash flows, future peak sales and market share for various products, potential
future products, our plans to acquire Opiant, potential plans to deploy cash
or return capital, future expenditures for research and development, SG&A;
future inorganic growth initiatives, our ability to optimize or scale our
business model, our intention to list on Nasdaq, and other statements
containing the words "strategy," "priorities," "strategic priorities,"
"target,' "plans," "opportunities," "believe," "anticipate," "expect,"
"potential," "intend," "estimate," "project," "may," "will," "should,"
"would," "could," "can," and variations thereon and similar expressions.

The forward-looking statements in this presentation are based on numerous
assumptions regarding our present and future business strategy and the
environment in which we operate, which may prove to be inaccurate. These
forward-looking statements are not guarantees of future performance and actual
results may differ materially from those expressed or implied in these
forward-looking statements. Various factors may cause differences between
Indivior's expectations and actual results including, among others, the risk
factors described in the most recent Indivior PLC Annual Report and in
subsequent press releases, and: our reliance on third parties to manufacture
commercial supplies of most of our products, conduct our clinical trials and
at times to collaborate on products in our pipeline; our ability to comply
with legal and regulatory settlements, healthcare laws and regulations,
requirements imposed by regulatory agencies and payment and reporting
obligations under government pricing programs; the substantial litigation and
ongoing investigations to which we are or may become a party; risks related to
the manufacture and distribution of our products, some of which are controlled
substances; market acceptance of our products as well as our ability to
commercialize our products and compete with other market participants;
uncertainties related to the development of new products, including through
acquisitions, and the related regulatory approval process; our dependence on a
small number of significant customers; our ability to retain key personnel or
attract new personnel; our dependence on third-party payors for the
reimbursement of our products and the increasing focus on pricing and
competition in our industry; unintended side effects caused by the clinical
study or commercial use of our products; our use of hazardous materials in our
manufacturing facilities; our import, manufacturing and distribution of
controlled substances; our ability to successfully execute acquisitions,
partnerships, joint ventures, dispositions or other strategic acquisitions;
the pending acquisition of Opiant may not close as expected, and we may not
achieve the contemplated benefits from the Opiant acquisition; our ability to
protect our intellectual property rights and the substantial cost of
litigation or other proceedings related to intellectual property rights; risks
related to product liability claims or product recalls; the significant amount
of laws and regulations that we are subject to, including due to the
international nature of our business; macroeconomic trends and other global
developments such as the COVID-19 pandemic; the terms of our debt instruments,
changes in our credit ratings and our ability to service our indebtedness and
other obligations as they come due; and changes in applicable tax rate or tax
rules, regulations or interpretations and our ability to realize our deferred
tax assets.

Forward-looking statements speak only as of the date that they are made and
should be regarded solely as expressions of our current plans, estimates and
beliefs. Except as required by law, we do not undertake and specifically
decline any obligation to update, republish or revise forward-looking
statements to reflect future events or circumstances or to reflect the
occurrences of unanticipated events.

Important Information for Investors and Stockholders

This communication does not constitute a solicitation of any vote or approval.
Opiant intends to file with the SEC and mail to its stockholders a definitive
proxy statement in connection with the proposed transactions. OPIANT'S
STOCKHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY
STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED WITH THE SEC WHEN
THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT
OPIANT AND THE PROPOSED MERGER. Investors and stockholders may obtain copies
of the proxy statement and other documents filed with the SEC by Opiant (when
they became available) free of charge from the SEC's website at www.sec.gov or
by accessing Opiant's website at www.opiant.com. Copies of the documents filed
with the SEC by Indivior (when they become available) may be obtained free of
charge from the SEC's website at www.sec.gov or by accessing Indivior's
website at www.indivior.com.

Participants in the Merger Solicitation

Indivior, Opiant, and certain of their directors, executive officers and
employees may be considered participants in the solicitation of proxies from
Opiant's stockholders with respect to the proposed transactions. Information
regarding the persons who may, under SEC rules, be deemed participants in the
solicitation of Opiant's stockholders in connection with the proposed merger
and a description of their direct and indirect interests, by security holdings
or otherwise, will be set forth in the definitive proxy statement that Opiant
intends to file with the SEC when it becomes available. Information about
Indivior's directors and executive officers is set forth in Indivior's Annual
Report and Accounts 2021 available at www.individior.com. Information about
Opiant's directors and executive officers is set forth in Opiant's definitive
proxy statement for its 2022 Annual Meeting of Stockholders, which was filed
with the SEC on April 18, 2022. These documents may be obtained as indicated
above.

 

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPGWWPUPPPPQ